Anteris Technologies Global Corp. AVR
Industrial Specialties · IPO 2024 · data as of November 13, 2026
Anteris Technologies Global Corp. (AVR) is a healthcare company listed in the US with a market value of about $528M. In the twelve months to September 30, 2026 it had revenue of $2M and net income of -$108M, a net margin of -4637.5%.
Its overall Stock Analiz score is 0.6 out of 5 (weak). The strongest part is future growth (1/5); the weakest is value (0/5).
Key numbers: a 5-year average ROIC of -2206%.
About Anteris Technologies Global
Anteris Technologies Global is listed in the US and classified in industrial specialties, IPO year 2024. It was profitable in 0 of the last 2 years in our data. It spends 3613% of revenue on research and development.
Score: 0.6 / 5
Checks passed
- Strong R&D investment or growth above 20%
- ROE above 15%
- More cash than debt, or low debt to equity
Checks not passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- Revenue growth above 10% last year
- 3-year revenue growth above 10% a year
- Profit margin improving
Valuation
Growth and quality
Financials, last 2 years
| Fiscal year | TTM | 2025 | 2024 |
|---|---|---|---|
| Revenue | $2M | $2M | $3M |
| Net income | -$108M | -$94M | -$76M |
| Free cash flow | -$93M | -$80M | -$64M |
| EPS (diluted) | $-1.61 | $-2.55 | $-3.68 |
| Net margin | -4637.5% | -4921.3% | -2822.5% |
| ROIC | — | -4289.4% | -122.2% |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
What analysts expect
The average 12-month price target from 4 analysts is $13.75, 154% above the current price; targets range from $9.00 to $16.00; the consensus rating is “Strong buy”; expected EPS is $-1.07 for the fiscal year ending December 31, 2026.
Frequently asked questions
Does Anteris Technologies Global pay a dividend?
Not currently.
Is Anteris Technologies Global a good stock to buy?
We do not give buy or sell advice. Anteris Technologies Global scores 0.6 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.